Actively Recruiting
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Led by Alnylam Pharmaceuticals · Updated on 2026-05-14
125
Participants Needed
16
Research Sites
286 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
CONDITIONS
Official Title
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Has documented diagnosis of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
- Has a documented transthyretin (TTR) gene variant
- Has a neuropathy impairment score (NIS) between 5 and 130 inclusive
- Has a Karnofsky Performance Status (KPS) of 60% or higher
You will not qualify if you...
- Has had a liver transplant or is likely to undergo liver transplantation during the study treatment period
- Has other known forms of amyloidosis besides hATTR or signs of leptomeningeal amyloidosis
- Has New York Heart Association (NYHA) heart failure classification greater than 2
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels more than 2.5 times the upper limit of normal
- Has total bilirubin level greater than 1.5 times the upper limit of normal
- Has estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m2
- Has other known causes of sensorimotor or autonomic neuropathy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
Clinical Trial Site
Baltimore, Maryland, United States, 21287
Actively Recruiting
2
Clinical Trial Site
Boston, Massachusetts, United States, 02118
Actively Recruiting
3
Clinical Trial Site
Dallas, Texas, United States, 75246
Actively Recruiting
4
Clinical Trial Site
São Paulo, Brazil, 04038-002
Actively Recruiting
5
Clinical Trial Site
Le Kremlin-Bicêtre, France, 94270
Actively Recruiting
6
Clinical Trial Site
Florence, Italy, 50134
Actively Recruiting
7
Clinical Trial Site
Milan, Italy, 20133
Actively Recruiting
8
Clinical Trial Site
Suita, Japan, 565-0871
Actively Recruiting
9
Clinical Trial Site
Kuala Lumpur, Malaysia, 59100
Actively Recruiting
10
Clinical Trial Site
Porto, Portugal, 4099-001
Not Yet Recruiting
11
Clinical Trial Site
Seoul, South Korea, 05030
Actively Recruiting
12
Clinical Trial Site
Seoul, South Korea, 06351
Actively Recruiting
13
Clinical Trial Site
Stockholm, Sweden, 113 61
Actively Recruiting
14
Clinical Trial Site
Umeå, Sweden, 907 37
Actively Recruiting
15
Clinical Trial Site
Taipei, Taiwan, 112
Not Yet Recruiting
16
Clinical Trial Site
Taoyuan City, Taiwan, 333
Actively Recruiting
Research Team
C
Clinical Trial Information Line
CONTACT
C
Clinical Trial Information Line
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here